{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:06:57Z","timestamp":1761581217516},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/pcan.2014.27","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T10:28:37Z","timestamp":1406024917000},"page":"292-299","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate"],"prefix":"10.1038","volume":"17","author":[{"given":"W","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J O","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E J","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"BFpcan201427_CR1","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2011.35.2005","volume":"29","author":"CJ Ryan","year":"2011","unstructured":"Ryan CJ, Tindall DJ . Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651\u20133658.","journal-title":"J Clin Oncol"},{"issue":"1\u20136 Spec No","key":"BFpcan201427_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0960-0760(95)00230-8","volume":"56","author":"R De Coster","year":"1996","unstructured":"De Coster R, Wouters W, Bruynseels J . P450-dependent enzymes as targets for prostate cancer therapy. JSteroid Biochem Mol Biol 1996; 56 (1\u20136 Spec No): 133\u2013143.","journal-title":"JSteroid Biochem Mol Biol"},{"key":"BFpcan201427_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0960-0760(03)00070-0","volume":"84","author":"S Haidar","year":"2003","unstructured":"Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW . Effects of novel 17alpha-hydroxylase\/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. JSteroid Biochem Mol Biol 2003; 84: 555\u2013562.","journal-title":"JSteroid Biochem Mol Biol"},{"key":"BFpcan201427_CR4","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/jm00013a022","volume":"38","author":"GA Potter","year":"1995","unstructured":"Potter GA, Barrie SE, Jarman M, Rowlands MG . Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995; 38: 2463\u20132471.","journal-title":"J Med Chem"},{"key":"BFpcan201427_CR5","doi-asserted-by":"publisher","first-page":"38 e17","DOI":"10.1016\/j.urolonc.2013.03.007","volume":"32","author":"T Nishiyama","year":"2014","unstructured":"Nishiyama T . Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature. Urol Oncol 2014; 32: 38 e17\u201328.","journal-title":"Urol Oncol"},{"key":"BFpcan201427_CR6","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","volume":"66","author":"M Stanbrough","year":"2006","unstructured":"Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815\u20132825.","journal-title":"Cancer Res"},{"key":"BFpcan201427_CR7","doi-asserted-by":"publisher","first-page":"R175","DOI":"10.1530\/ERC-10-0339","volume":"18","author":"C Cai","year":"2011","unstructured":"Cai C, Balk SP . Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011; 18: R175\u2013R182.","journal-title":"Endocr Relat Cancer"},{"key":"BFpcan201427_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.mce.2008.08.013","volume":"295","author":"PR Dillard","year":"2008","unstructured":"Dillard PR, Lin MF, Khan SA . Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295: 115\u2013120.","journal-title":"Mol Cell Endocrinol"},{"key":"BFpcan201427_CR9","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","volume":"68","author":"JA Locke","year":"2008","unstructured":"Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407\u20136415.","journal-title":"Cancer Res"},{"key":"BFpcan201427_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995\u20132005.","journal-title":"N Engl J Med"},{"key":"BFpcan201427_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138\u2013148.","journal-title":"N Engl J Med"},{"key":"BFpcan201427_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"CJ Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481\u20131488.","journal-title":"J Clin Oncol"},{"key":"BFpcan201427_CR13","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563\u20134571.","journal-title":"J Clin Oncol"},{"key":"BFpcan201427_CR14","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2002.10.018","volume":"20","author":"EP Gelmann","year":"2002","unstructured":"Gelmann EP . Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001\u20133015.","journal-title":"J Clin Oncol"},{"key":"BFpcan201427_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/jm0005353","volume":"44","author":"CA Marhefka","year":"2001","unstructured":"Marhefka CA, Moore BM 2nd, Bishop TC, Kirkovsky L, Mukherjee A, Dalton JT et al. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem 2001; 44: 1729\u20131740.","journal-title":"J Med Chem"},{"key":"BFpcan201427_CR16","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1073\/pnas.0408819102","volume":"102","author":"F Schaufele","year":"2005","unstructured":"Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 2005; 102: 9802\u20139807.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpcan201427_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1021\/cb900024z","volume":"4","author":"JO Jones","year":"2009","unstructured":"Jones JO, An WF, Diamond MI . AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol 2009; 4: 199\u2013208.","journal-title":"ACS Chem Biol"},{"key":"BFpcan201427_CR18","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","volume":"10","author":"T Nishiyama","year":"2004","unstructured":"Nishiyama T, Hashimoto Y, Takahashi K . The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10: 7121\u20137126.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201427_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","volume":"10","author":"JL Mohler","year":"2004","unstructured":"Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440\u2013448.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201427_CR20","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447\u20134454.","journal-title":"Cancer Res"},{"key":"BFpcan201427_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nm0497-402","volume":"3","author":"KA Klein","year":"1997","unstructured":"Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3: 402\u2013408.","journal-title":"Nat Med"},{"key":"BFpcan201427_CR22","first-page":"115","volume":"37","author":"JS Horoszewicz","year":"1980","unstructured":"Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L et al. The LNCaP cell line\u2014a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980; 37: 115\u2013132.","journal-title":"Prog Clin Biol Res"},{"key":"BFpcan201427_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33\u201339.","journal-title":"Nat Med"},{"key":"BFpcan201427_CR24","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1073\/pnas.0807282106","volume":"106","author":"JO Jones","year":"2009","unstructured":"Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 2009; 106: 7233\u20137238.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpcan201427_CR25","first-page":"8712","volume":"61","author":"CY Chang","year":"2001","unstructured":"Chang CY, Walther PJ, McDonnell DP . Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 2001; 61: 8712\u20138717.","journal-title":"Cancer Res"},{"key":"BFpcan201427_CR26","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","volume":"72","author":"J Richards","year":"2012","unstructured":"Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012; 72: 2176\u20132182.","journal-title":"Cancer Res"},{"key":"BFpcan201427_CR27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309\u20131322.","journal-title":"Cell"},{"key":"BFpcan201427_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","volume":"31","author":"IA Luthy","year":"1988","unstructured":"Luthy IA, Begin DJ, Labrie F . Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988; 31: 845\u2013852.","journal-title":"J Steroid Biochem"},{"key":"BFpcan201427_CR29","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/jco.2012.30.15_suppl.4521","volume":"30","author":"ME Taplin","year":"2012","unstructured":"Taplin ME, Montgomery RB, Logothetis C, Bubley GJ, Richie JP, Dalkin BL et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study. J Clin Oncol 2012; 30: 4521.","journal-title":"J Clin Oncol"},{"key":"BFpcan201427_CR30","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1200\/jco.2012.30.15_suppl.4556","volume":"30","author":"E Efstathiou","year":"2012","unstructured":"Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S et al. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): preliminary results of a randomized preoperative study. J Clin Oncol 2012; 30: 4556.","journal-title":"J Clin Oncol"},{"key":"BFpcan201427_CR31","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/j.1349-7006.2010.01620.x","volume":"101","author":"M Uemura","year":"2010","unstructured":"Uemura M, Honma S, Chung S, Takata R, Furihata M, Nishimura K et al. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Sci 2010; 101: 1897\u20131904.","journal-title":"Cancer Sci"},{"key":"BFpcan201427_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239\u2013243.","journal-title":"Nature"},{"key":"BFpcan201427_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11\u201322.","journal-title":"Cancer Cell"},{"key":"BFpcan201427_CR34","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63: 920\u2013926.","journal-title":"Eur Urol"},{"key":"BFpcan201427_CR35","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","volume":"3","author":"M Korpal","year":"2013","unstructured":"Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013; 3: 1030\u20131043.","journal-title":"Cancer Discov"},{"key":"BFpcan201427_CR36","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1210\/jc.2006-0968","volume":"91","author":"ST Page","year":"2006","unstructured":"Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91: 3850\u20133856.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201427_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197.","journal-title":"N Engl J Med"},{"key":"BFpcan201427_CR38","doi-asserted-by":"crossref","unstructured":"Beer TM, Armstrong AJ, Sternberg CN, Higano C, Iverson P, Loriot Y et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. J Clin Oncol 2014; 32, LBA1.","DOI":"10.1200\/jco.2014.32.4_suppl.lba1"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201427","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:39:45Z","timestamp":1648676385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFpcan201427"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2014.27","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]},"assertion":[{"value":"23 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM is an employee of Johnson & Johnson and holds stock ownership. CH is a former employee of Johnson & Johnson and holds stock ownership. CJR has received honoraria from Janssen. JM is a member of the NCCN's Prostate Cancer Early Detection Panel and, on behalf of the NCCN, has received honoraria only for lectures (usually annual meeting for guidelines update and occasional CME activity) or other activities (panel participation for guidelines adaptation for other countries); has received an honorarium from the Genomic Health Scientific Advisory Board (related activity: presentation (no honorarium), collaboration with the North Carolina-Louisiana Prostate Cancer Project (no funded effort or honorarium)); is a cofounder and chief medical officer of AndroBioSys, with ownership interest (value: none); is associated with Medivation MTA for MDV3100 (no research support or honoraria); is a consultant to and collaborator on research at New York University School of Medicine; and was an initial investor (value: none) in and an advisory board member for Simulated Surgical Systems. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}